LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Principles for Genetic Testing and Testing for Genetically-Driven Risk Factor

13/12/2022
REPORT

EuropaBio Principles for Genetic Testing and Testing for Genetically Driven Risk Factors

Executive Summary

Advances in science and technology have greatly improved our understanding of the genetic basis of disease, which have made it possible to redefine many diseases at higher resolution and target them with more precise treatments such as cell and gene therapies.

Increased access to genetic testing is a significant opportunity for patients and healthcare systems in Europe by supporting the deployment of targeted therapeutic strategies. With knowledge, people at risk of developing diseases may take steps towards prevention. New therapies can transform lives if they reach the right patients at the right time. Whether for screening, early or confirmatory diagnosis, or patient stratification, genetic testing can support medical decision-making, empowering patients and helping healthcare systems use the most appropriate treatments.

To support the uptake of genetic testing, EuropaBio propose a set of 12 policy principles and associated recommendations across the following areas:

  • Regulatory pathways
  • Funding and access
  • Infrastructure and workforce
  • Ethics and society

EuropaBio invite policy-makers and other relevant stakeholders to engage with us on this topic and unlock the path of innovation for next generation medicines to the benefit of European patients, healthcare systems, and society.

  • Principle 1: Regulatory frameworks should not be contradictory. They should be adapted to appropriately assess available evidence for novel technologies.
  • Principle 2: Value assessment evidence requirements for innovative tests should be aligned and harmonised across the EU. This requires dialogue between regulators, HTA bodies, payers, physicians, innovators and patients.
  • Principle 3: Decision makers at all levels should coordinate to prevent access delays to screening and testing.
  • Principle 4: Decision makers should consider the benefits of testing and screening to patients, society and the medical community, including long-term cost savings and the value of knowing for patients, when assessing technologies, diseases or biomarkers to inform funding and coverage decisions.
  • Principle 5: Decision makers should define clear value considerations for diagnostic technologies, including for tests which are not associated with a particular intervention and RWE accepted where appropriate.
  • Principle 6: Responsibility for funding of diagnostics and screening lies with public health bodies, but industry may have a role to play in certain situations. Specific budget should be allocated for testing, anticipated via horizon scanning and integrated with other healthcare budgets.
  • Principle 7: Investments in infrastructure, including in data analytics services, electronic health records, diagnostic equipment and laboratory capacity are needed to scale up testing and screening programs in the clinical setting.
  • Principle 8: Healthcare professionals, including non-specialists, must be trained on screening and testing to increase uptake/ prescription and correct application and interpretation of tests.
  • Principle 9: Diagnostic screening or testing should be available when a treatment is available. To allow patients to benefit from a treatment as soon as possible, the environment should be prepared in advance of the treatment’s availability. Coordination between regulators, HTA, payers, policymakers, manufacturers, physicians, and patients is needed to make tests available with diagnosis and treatment guidelines available.
  • Principle 10: A positive test result should lead to clear action, such as treatment, management or lifestyle changes.
  • Principle 11: Populations (age- or risk-based) should be screened where the best clinical outcome arises from intervening before the patient shows symptoms.
  • Principle 12: Testing for genes or biomarkers that indicate risk of developing disease should be based on informed consent and be available to individuals for whom there is evidence that identifying risks can improve outcomes.

Click on the button below to read the full report.

EuropaBio Principles for Genetic Testing and Testing for Genetically-Driven Risk Factor


Download

2022_13_HC_O_EuropaBio-Principles-for-Genetic-TestingDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
24/03/2025

Response to the EC Call for Evidence for an evaluation of ”EU rules on medical devices and in vitro diagnostics”


Read more
19/03/2025

Measuring the Economic Footprint of the Biotechnology Industry in the European Union


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.